Abbott Laboratories $ABT is Orion Investment Co’s 8th Largest Position

Orion Investment Co trimmed its stake in shares of Abbott Laboratories (NYSE:ABT) by 2.6% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 65,643 shares of the healthcare product maker’s stock after selling 1,785 shares during the period. Abbott Laboratories accounts for 3.6% of Orion Investment Co’s portfolio, making the stock its 8th largest holding. Orion Investment Co’s holdings in Abbott Laboratories were worth $8,708,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of ABT. Brighton Jones LLC grew its stake in Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after acquiring an additional 4,755 shares in the last quarter. Bank Pictet & Cie Europe AG grew its stake in shares of Abbott Laboratories by 1.9% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock worth $17,274,000 after buying an additional 2,774 shares in the last quarter. Voleon Capital Management LP purchased a new position in shares of Abbott Laboratories in the 4th quarter worth $273,000. Rehmann Capital Advisory Group grew its stake in shares of Abbott Laboratories by 2.6% in the 4th quarter. Rehmann Capital Advisory Group now owns 11,753 shares of the healthcare product maker’s stock worth $1,329,000 after buying an additional 298 shares in the last quarter. Finally, Parvin Asset Management LLC purchased a new position in shares of Abbott Laboratories in the 4th quarter worth $963,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.46% of the stock is owned by insiders.

Abbott Laboratories Trading Down 0.1%

Shares of ABT opened at $131.39 on Thursday. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23. The company has a 50-day moving average of $131.01 and a 200 day moving average of $131.33. The firm has a market capitalization of $228.68 billion, a price-to-earnings ratio of 16.47, a PEG ratio of 2.50 and a beta of 0.70. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The company had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. During the same quarter last year, the business posted $1.14 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were issued a dividend of $0.59 per share. The ex-dividend date was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Analysts Set New Price Targets

A number of equities analysts have commented on ABT shares. Jefferies Financial Group raised shares of Abbott Laboratories from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Royal Bank Of Canada lifted their price objective on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 15th. Evercore ISI lifted their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 8th. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a “market perform” rating and a $143.00 price objective for the company. Finally, Leerink Partnrs raised shares of Abbott Laboratories to a “hold” rating in a research note on Monday, June 16th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $144.47.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.